Inclusion Criteria:

- histologically or cytologically confirmed diagnosis with evidence of either
metastatic disease (Stage IV) of locally recurrent disease not amenable to curative
resection or radiation therapy (Stage IIIB).

- Her-2negative breast cancer or unknown Her-2 status.

- at least 1 measurable lesion as defined by RECIST.

- ECOG status 0-1

- adequate bone marrow, hepatic and renal function.

- left ventricular ejection fraction of greater than or equal to 50%.

- willingness to discontinue hormonal therapy.

Exclusion Criteria:

- any previous chemotherapy for advanced disease.

- prior exposure to taxanes as (neo) adjuvant treatment less than 12 months prior to
randomization.

- symptomatic brain metastases.

- prior anti-IGF-1R based investigational therapy.

- peripheral neuropathy greater than grade 2.